<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417647</url>
  </required_header>
  <id_info>
    <org_study_id>G-Wound_01</org_study_id>
    <nct_id>NCT04417647</nct_id>
  </id_info>
  <brief_title>G-Wound (VZ for Wound Treatment)</brief_title>
  <official_title>A Prospective, Randomized, Open-label, Controlled, Exploratory Trial to Investigate the Safety and Tolerability of Topically Administered VZ in Healthy Male Subjects With Artificial Dermal Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glock Health, Science and Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glock Health, Science and Research GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, open-label, controlled, exploratory trial that aims to
      investigate the local skin tolerability of topically administered VZ and to evaluate efficacy
      and safety parameters associated with improved wound condition and healing
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tolerability of IMD</measure>
    <time_frame>14 days</time_frame>
    <description>Local tolerability of IMD assessed using erythema severity score: a scale from 0 - 4 (0 = no visible reaction, 1 = faint, minimal erythema, 2 = erhythema, 3 = erythema with induration of vesicles, 4 = severe erythema with induration, vesicles or bullae or pustules and/ulceration) with 0 being best and 4 being worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in wound size</measure>
    <time_frame>14 days</time_frame>
    <description>Change in wound size between baseline and End of Treatment (EoT) assessed by photographic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound closure</measure>
    <time_frame>1 day</time_frame>
    <description>Presence or absence of complete wound closure at End of Treatment (EoT) visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing and condition</measure>
    <time_frame>14 days</time_frame>
    <description>Wound healing and wound condition parameters assessed as a dichotomous outcome by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological evaluation</measure>
    <time_frame>2 days</time_frame>
    <description>Descriptive histological evaluation of wound healing by H&amp;E and Masson trichrome staining as well as by immunostaining against biomarkers of the biopsy specimens obtained at baseline and at EoT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's satisfaction on topical applicability</measure>
    <time_frame>14 days</time_frame>
    <description>Investigator's satisfaction on topical applicability of VZ evaluated via a 5-point Likert scale: a scale from 1 - 5: 5 = extremely satisfied, 4 = very satisfied, 3 = moderately satisfied, 2 = slightly satisfied, 1 = not at all satisfied) with 5 being best and 1 being worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in local pain intensity</measure>
    <time_frame>14 days</time_frame>
    <description>Change in local pain intensity based on the Visual Analogue Scale (VAS) when compared to SoC-treated wounds with a scale from 0-10: 0 - no pain and 10 - worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Wounds</condition>
  <condition>Wound Heal</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proximal wound SoC treatment - Distal wound VZ application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Distal wound SoC treatment - Proximal wound VZ application</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VZ powder (purified clinoptilolite)</intervention_name>
    <description>VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care (SoC)</intervention_name>
    <description>wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects

          2. Age 18-45 years at time of screening

          3. Subjects are in good clinical and mental health as established by medical history and
             physical examination

          4. Subject agrees to be compliant with study related visit and treatment schedule

          5. Written informed consent

        Exclusion Criteria:

          1. Regular use of medications affecting the blood clotting process (e.g. aspirin or any
             other over-the-counter medicine or complimentary health product affecting the blood
             clotting process) or immunosuppressive drugs. Aspirin should not be taken in the 10
             days prior to study participation or during the study

          2. Use of topical (in the skin area of investigation) or systemic antibiotics within the
             last 4 weeks before study enrolment

          3. History of cancer (except for non-melanoma skin cancer) within the previous 12 months
             or treatment with anticancer therapy (chemotherapy, immunotherapy, radiotherapy,
             hormone therapy for cancer treatment, targeted therapy or gene therapy) within 12
             months before the first administration of investigational product or at any time
             during the study

          4. Subjects with any known coagulation disorder

          5. Subjects who have pigmented skin (Fitzpatrick Classification Level V - VI) due to an
             increased susceptibility to hypertrophic and keloid scarring

          6. History of wound healing abnormalities or a medical condition that is known to be
             associated with abnormal wound healing

          7. Chronic inflammatory dermatological disease

          8. History of chronic autoimmune diseases such as, but not restricted to rheumatoid
             arthritis, inflammatory bowel disease, lupus erythematodes

          9. Subjects diagnosed with Diabetes Type I or II

         10. Lack of 2-point discrimination above 10 cm as assessed using an aesthesiometer

         11. Tattoos, scars, burns, rashes or hyper- or hypopigmentation in the region of planned
             punch biopsy

         12. Evidence of active infectious disease including HIV and hepatitis B or C

         13. Current smoker (or any kind of nicotine consumption)

         14. Known allergies to biopsy numbing medication, wound cleansing solution and wound
             dressing

         15. Known hypersensitivity to aluminium and/or silicon

         16. Allergy requiring medical treatment within the last 4 weeks prior to screening

         17. Active infection or fever &gt; 38°C within the last 7 days prior to randomization

         18. Clinically relevant abnormalities in the laboratory testing, vital signs, ECG or
             physical examination

         19. Alcohol abuse or a positive urine screen for drugs of abuse at screening

         20. Participation in another clinical trial with an investigational day within the last 4
             weeks before study participation

         21. Employee at the study site, spouse/partner or relative of any study staff (e.g.
             investigator, sub-investigators, or study nurse) or relationship to the sponsor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wolzt, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wound</keyword>
  <keyword>Healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

